Searchable abstracts of presentations at key conferences in endocrinology

ea0077hdi1.6 | How do I. . .? 1 | SFEBES2021

How do I optimise thyroid status after RAI therapy?

Zammitt Nicola

First, it is pertinent to ask WHY we should optimise thyroid status after RAI therapy. The links between poorly controlled thyroid function and patients’ wellbeing, weight and thyroid eye symptoms will be discussed. This talk will also outline the use of block and replace therapy to reduce the risk of thyroid hormone instability following RAI....

ea0028p360 | Thyroid | SFEBES2012

Predicting risk of relapse following thionamide withdrawal in Graves’ disease

Gibb Fraser , Strachan Mark , Zammitt Nicola

Background: Male sex, cigarette smoking, young age, severe thyrotoxicosis, large goitre and marked or persistent elevation of TRABs are consistently reported as predictors of relapse following withdrawal of thionamides in Graves’ disease. Early recurrence rates are commonly quoted at 50% but the definition of early recurrence varies widely across the literature. AIM We sought to determine the best clinical predictors of recurrent thyrotoxicosis and whether these would per...

ea0050p393 | Thyroid | SFEBES2017

Long-term relapse rates following thionamide withdrawal in Graves’ thyrotoxicosis and the predictive role of TRAbs

Tun Nyo Nyo , Gibb Frase , Strachan Mark , Zammitt Nicola

Background: Thionamides are a safe and effective treatment for Graves’ thyrotoxicosis and tend to be favoured over radioiodine in the UK. Risk of recurrence following cessation of thionamides is high although most studies tend to have short duration of follow up. We have previously published follow-up data to 4 years in this cohort and now present follow-up out to 7 years.Methods: Retrospective review of first presentation Graves’...

ea0050p393 | Thyroid | SFEBES2017

Long-term relapse rates following thionamide withdrawal in Graves’ thyrotoxicosis and the predictive role of TRAbs

Tun Nyo Nyo , Gibb Frase , Strachan Mark , Zammitt Nicola

Background: Thionamides are a safe and effective treatment for Graves’ thyrotoxicosis and tend to be favoured over radioiodine in the UK. Risk of recurrence following cessation of thionamides is high although most studies tend to have short duration of follow up. We have previously published follow-up data to 4 years in this cohort and now present follow-up out to 7 years.Methods: Retrospective review of first presentation Graves’...

ea0065p148 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

An audit on a teenage and young adult (TYA) neuro-oncology and late effects clinic

Chow Anthea , Zammitt Nicola N , Wright Rohana J

Introduction: Due to improved cancer survival rates, a rising number of CNS cancer survivors face late effects of therapy, such as hormone deficiencies. During adolesecence and young adulthood, specialised transition services are needed to cater for young peoples complex health needs and general needs, such as achieving independence. This study therefore audited a Teenage & Young Adult (TYA) neuro-oncology late effects clinic to identify areas of good practice and areas fo...

ea0028p41 | Clinical practice/governance and case reports | SFEBES2012

Low prevalence of pituitary pathology in men presenting with isolated hypogonadotrophic hypogonadism

Gibb Fraser , Strachan Mark , Zammitt Nicola , Walker Brian

Background: Male hypogonadotrophic hypogonadism is an increasingly common cause of referral to endocrine clinics. Subnormal testosterone levels are frequently observed in obesity, type 2 diabetes mellitus and in the elderly. Endocrine Society guidelines suggest stratification of investigations based on the degree of androgen deficiency, with full pituitary function testing and MRI recommended only in those with serum testosterone levels less than 5.2 nmol/L. However the eviden...

ea0044p236 | Thyroid | SFEBES2016

Increasing awareness of Graves’ orbitopathy with “Early Warning” cards – a TEAMeD multicentre quality improvement project

Mitchell Anna L , Zammitt Nicola , Ajjan Ramzi , Vaidya Bijay , Hickey Janis , Perros Petros , Dayan Colin

Background: Clinically significant Graves’ orbitopathy (GO) develops in 20% of those with Graves’ Disease (GD). Up to 90% of cases present at the same time as, or after, hyperthyroidism develops. Most cases of GD in the UK are managed in endocrinology clinics. Despite this, patients report significant delays before a correct diagnosis of GO is made. We argued that measures to increase awareness of the early signs of GO in those with GD and establishing a fast-track r...

ea0077oc6.1 | Thyroid | SFEBES2021

Adjuvant Rituximab – exploratory trial in young people with Graves’ disease

Cheetham Tim , Cole Michael , Abinun Mario , Alalhabadia Amit , Barratt Tim , Davies Justin , Dimitri Paul , Drake Amanda , Mohamed Zainaba , Murray Robert , Steele Caroline , Zammitt Nicola , Carnell Sonya , Prichard Jonathan , Watson Gillian , Hambleton Sophie , Matthews John , Pearce Simon

Objective: Remission rates in young people with Graves’ hyperthyroidism are <25% after a 2-yr course of thionamide antithyroid drug (ATD). Immunomodulatory agents might improve outcome by facilitating immune tolerance. We explored whether rituximab (RTX) would increase remission rates when administered with a short course of ATD.Design: This was an open label multi-centre single arm phase 2 trial in newly presenting young people (12-20y) with Gr...